NICE recommends secukinumab with three-month window for NHS implementation

Secukinumab is an innovative new treatment licensed for use in adults with moderate-to-severe plaque psoriasis

Source: Pharmacy Europe - July 22, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Dermatology Patient care Cosentyx Latest News nice plaque psoriasis secukinumab Source Type: news